跳到主要导航 跳到搜索 跳到主要内容

Bioactive glass in the treatment of ulcerative colitis to regulate the TLR4 / MyD88 / NF-κB pathway

  • Wenhao Wang
  • , Shengyuan Jia
  • , Guohou Miao
  • , Zhenmin Sun
  • , Feng Yu
  • , Zhixing Gao
  • , Yuli Li
  • Qingdao Municipal Hospital
  • Weifang Medical University
  • Affiliated Stomatology Hospital of Guangzhou Medical University
  • Hainan University

科研成果: 期刊稿件文章同行评审

8 引用 (Scopus)

摘要

Ulcerative colitis (UC) is a chronic and recurrent intestinal disease of unknown aetiology, and the few treatments approved for UC have serious side effects. In this study, a new type of uniformly monodispersed calcium-enhanced radial mesoporous micro-nano bioactive glass (HCa-MBG) was prepared for UC treatment. We established cellular and rat UC models to explore the effects and mechanism of HCa-MBG and traditional BGs (45S5, 58S) on UC. The results showed that BGs significantly reduced the cellular expression of several inflammatory factors, such as IL-1β, IL-6, TNF-α and NO. In the animal experiments, BGs were shown to repair the DSS-damaged colonic mucosa. Moreover, BGs downregulated the mRNA levels of the inflammatory factors IL-1β, IL-6, TNF-α and iNOS, which were stimulated by DSS. BGs were also found to manage the expression of key proteins in NF-kB signal pathway. However, HCa-MBG was more effective than traditional BGs in terms of improving UC clinical manifestations and reducing the expression of inflammatory factors in rats. This study confirmed for the first time that BGs can be used as an adjuvant drug in UC treatment, thereby preventing UC progression.

源语言英语
文章编号213520
期刊Biomaterials Advances
152
DOI
出版状态已出版 - 9月 2023

指纹图谱

探究 'Bioactive glass in the treatment of ulcerative colitis to regulate the TLR4 / MyD88 / NF-κB pathway' 的科研主题。它们共同构成独一无二的指纹。

引用此